The International Liver Congress™ 2022 (ILC 2022)

Is bulevirtide a potential answer for chronic hep D?

Roshini Claire Anthony, 20220820110001

Bulevirtide at a dose of 2 mg or 10 mg daily induces biochemical and virological response in patients with chronic hepatitis D virus (HDV) infection, according to results of Study MYR301.

Real-world studies demonstrate TAF efficacy and safety in chronic hep B

Roshini Claire Anthony, 20220720170002

Treatment with tenofovir alafenamide (TAF) results in similar virological response compared with tenofovir disoproxil fumarate (TDF) in treatment-naïve patients with chronic hepatitis B (CHB), according to a real-world study from Korea presented at ILC 2022.

Unexplained hepatitis outbreak in kids: Are COVID-19, adenovirus the triggers?

Elvira Manzano, 20220719160000

Cases of acute, severe hepatitis of unknown aetiology in young children have increased recently and investigations are underway, says an expert during a media briefing at ILC 2022.

Resmetirom demos potential in NASH

Roshini Claire Anthony, 20220718150001

Safety analysis of the phase III MAESTRO-NAFLD-1 trial presented at ILC 2022 demonstrated the potential of resmetirom as a treatment for patients with non-alcoholic steatohepatitis (NASH) who have liver fibrosis.

Less liver fat, better glucose control with LCHF diet

Elvira Manzano, 20220718040000

A low-carbohydrate, high-fat (LCHF) diet averts disease progression in patients with nonalcoholic fatty liver disease (NAFLD) in a new study presented at ILC 2022.